Since testing for KRAS, BRAF, MSI/dMMR, MLH1, and possibly other genes constitutes a prerequisite of CRC diagnostics, panel-based assays are understandably more prominent in current pathological practice—in Germany, all major university and non-university institutions are now using focused NGS for this purpose. This evidence concerns the gene KRAS and colorectal carcinoma.